DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for immunodeficiency 85 and autoimmunity — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleImmunodeficiency 85 and autoimmunity maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for immunodeficiency 85 and autoimmunity is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
target of myb1 membrane trafficking protein (TOM1) — TOM1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1ELK · 1.5 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Common variable immunodeficiency (CVID) and other primary immunodeficiency disorders (PIDs) are frequently complicated by autoimmune and inflammatory conditions, a paradox that creates significant diagnostic and therapeutic challenges. Patients with CVID are characterised by increased susceptibility to infections and low serum immunoglobulin, but also commonly develop enteropathy, granulomatous organ infiltrates, malignancy, and inflammatory or autoimmune conditions. The management of autoimmunity in these patients requires special considerations because dysregulation and dysfunction of the immune system, along with persistent inflammation, impair the process of diagnosis and treatment.
Several mechanisms have been identified that link primary immunodeficiencies to autoimmunity. These include increased homeostatic proliferation in PIDs associated with lymphopenia, defects in regulatory T cells in Wiskott-Aldrich syndrome, and impairments in negative regulatory mechanisms of innate immune cells that can lead to inappropriate inflammation. The realisation that PIDs can impair negative regulation of immune responses has provided a new framework for understanding the associated autoimmunity and may lead to more targeted therapies for autoimmune complications in these patients.
Intravenous immunoglobulin is used as replacement therapy in primary immunodeficiency diseases and as an immunomodulatory agent in autoimmune and inflammatory disorders, though its mechanisms of action are complex and not well understood for some conditions. For severe combined immunodeficiency and combined immunodeficiency, therapeutic options range from prophylactic anti-infective measures to haematopoietic stem cell transplantation and gene therapy. For secondary immunodeficiency diseases, such as those arising from HIV or systemic lupus erythematosus, conventional treatments do not typically cure and their side effects can exacerbate the conditions; immunotherapy approaches are being explored as alternatives.
What remains missing are prospective trials that stratify patients by the specific genetic and immunological defects underlying their combined immunodeficiency and autoimmunity, as well as funding to develop and test targeted therapies that address the identified mechanisms of immune dysregulation rather than relying on broad immunosuppression or immunoglobulin replacement alone.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Expert Review of Clinical Immunology · 2016 · 77 citations
Autoimmunity in common variable immunodeficiency: epidemiology, pathophysiology and management
AbstractINTRODUCTION: Common variable immunodeficiency (CVID) comprises a large heterogeneous group of patients with primary antibody deficiency. Areas covered: The affected patients are characterized by increased susceptibility to infections and low levels of serum immunoglobulin. However, enteropathy, granulomatous organ infiltrates, malignancy, inflammatory and autoimmune conditions are also prevalent. The concomitance of immunodeficiency and autoimmunity appears to be paradoxical and creates difficulties in the management of autoimmune complications affecting these patients. Expert commentary: The management of autoimmunity in patients with CVID requires special considerations because dysregulation and dysfunctions of the immune system along with persistent inflammation impair the process of diagnosis and treatment.
Current Opinion in Rheumatology · 2008 · 71 citations · open access
Rheumatologic and autoimmune manifestations of primary immunodeficiency disorders
AbstractPURPOSE OF REVIEW: Although it may seem paradoxical, primary immunodeficiency disorders are frequently complicated by autoimmune and inflammatory conditions. These conditions pose significant diagnostic and therapeutic challenges for clinicians caring for these patients. There have been a number of new insights into how immunodeficiencies can predispose to autoimmunity, and rheumatologists should understand the basis for and manifestations of autoimmunity in primary immunodeficiency disorders to more effectively care for these patients. RECENT FINDINGS: A number of mechanisms have recently been found to link primary immunodeficiencies and autoimmunity, including increased homeostatic proliferation in primary immunodeficiencies associated with lymphopenia and defects in regulatory T cells in the Wiskott-Aldrich syndrome. Primary immunodeficiencies that affect the innate immune system can also lead to inappropriate inflammation through impairing negative regulatory mechanisms in innate immune cells. SUMMARY: The realization that primary immunodeficiencies can also impair negative regulation of immune responses has provided a new framework for the understanding of autoimmunity associated with these conditions. These insights may lead to new, more targeted therapies for autoimmune complications in primary immunodeficiency patients.
Scandinavian Journal of Immunology · 2016 · 57 citations
Approach to the Management of Autoimmunity in Primary Immunodeficiency
AbstractPrimary immunodeficiency diseases (PIDs) consist of a genetically heterogeneous group of immune disorders that affect distinct elements of the immune system. PID patients are more prone to infections and non-infectious complications, particularly autoimmunity. The concomitance of immunodeficiency and autoimmunity appears to be paradoxical and leads to difficulty in the management of autoimmune complications in PID patients. Therefore, management of autoimmunity in patients with PID requires special considerations because dysregulations and dysfunctions of the immune system along with persistent inflammation impair the process of diagnosis and treatment.
Current Opinion in Pediatrics · 1999 · 23 citations
Supply, use, and abuse of intravenous immunoglobulin
AbstractIntravenous immunoglobulin is used as a replacement therapy in primary immunodeficiency diseases as well as an immunomodulatory agent in a variety of autoimmune and inflammatory disorders. The mechanisms of intravenous immunoglobulin action are complex and, for some disorders, not well understood. This paper reviews the recent literature and discusses approved, new, and controversial indications for intravenous immunoglobulin therapy, with special emphasis on its mechanism of action.
Oxford University Press eBooks · 2013 · 0 citations
Introduction to Severe Combined Immunodeficiency (SCID) and Combined Immunodeficiency (CID)
AbstractPrimary immunodeficiency diseases are inherited disorders that affect human adaptive and innate immunity. In most cases, affected individuals experience recurrent infections, but they may also suffer from autoimmune diseases and malignancies. This chapter focuses on Introduction to Severe Combined Immunodeficiency (SCID) and Combined Immunodeficiency (CID) including the historic and scientific background, clinical presentations, immunologic characteristics, and the molecular/genetic underpinnings. Where appropriate, diagnostic tools and therapeutic options are outlined -- from prophylactic anti-infective measures to hematopoietic stem cell transplantation and gene therapy.
Cohesive Journal of Microbiology & Infectious Disease · 2020 · 0 citations · open access
AbstractThe inner workings of the immune system are quite complex. Each component works diligently in order to protect us from invaders such as pathogens: viruses, microbes, and fungi. Unfortunately, the immune system may become dysfunctional, which can result in secondary immunodeficiency diseases. The treatments available for these disorders and diseases of the immune system do not typically serve to cure, and much too often the side effects associated can exacerbate the conditions. As an alternative, the area of immunotherapy seeks to remedy the limitations of today's medicine. Through this review, insight into the current conventional treatments available for select secondary immunodeficiency diseases will be provided, particularly in Human Immunodeficiency Virus disease and Systemic Lupus Erythematosus. The modern immunotherapy approaches that are underway will then be analyzed in their capacity and potential to treat these defects of the immune system.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
